Skip to main content

Table 7 Characteristics of DrotAA-treated pediatric patients with PF, MEN, or MD and experienced a serious bleeding event

From: Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Characteristic

During infusion

 

After infusion

 

Day of event1

1

1

7

8

10

UD

UD

Bleeding event

       

   ICH

No

No

No

Yes

No

Yes

Yes

   Fatal

No

No

No

Yes

No

Yes

No

   DrotAA related2

No

No

No

Yes

No

No

No

Disease category

       

   PF

Yes

Yes

Yes

Yes

Yes

No

Yes

   MEN

No

Yes

No

No

No

Yes

No

   MD

Yes

Yes

Yes

Yes

Yes

Yes

No

Baseline characteristics

       

   Protein C level (%)

36

-

16

41

-

34

-

   Platelet count

26

23

33

30

68

71

14

   APTT (s)

68

165

121

220

73

111

-

   PT (s)

23

38

22

-

-

17

16

   Organ failure

3

4

3

4

1

-

-

  1. 1Day 0 is defined as the calendar day on which DrotAA treatment began; 2This denotes whether or not the investigator considered the bleeding event to be related to treatment with DrotAA. APTT, activated partial thromboplastin time; BL, baseline; DrotAA, drotrecogin alfa (activated); ICH, intracranial hemorrhage; PT, prothrombin time; UD, unknown day after infusion. A dash indicates missing data.